The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.

The initiative is a response to a Trump administration order to speed the construction of the type of new drug factories many pharmaceutical companies have promised to build.

While orforglipron succeeded in a Phase 3 trial, its weight loss effects were more modest than investors and analysts ...

The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to ...

The FDA had halted use in older adults while it investigated reports of side effects. The vaccine’s label now carries new ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to roll up their sleeves" and build out more direct-to ...

A spokesperson confirmed the company plans to reduce its workforce by “less than 20%,” months after significantly lowering ...

The biotech industry needs to be supported by the government, by Congress,” Pfizer’s Albert Bourla told investors Tuesday in ...

The investment, which the foundation says is its largest in women’s health, will support research in maternal health, ...

One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step ...